KRT-232

Phase 2Small molecule

KKartos Therapeutics, Inc.

KRT-232 is one of 226 small molecule programs targeting Polycythemia Vera. It is currently in Phase 2.

Indications

Total Trials

Active Trials

225

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polycythemia VeraActive, not recruiting

MyelofibrosisActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Merkel Cell CarcinomaActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Myeloid LeukemiaActive, not recruiting

Essential ThrombocythemiaActive, not recruiting

Polycythemia VeraPhase 2

Active, not recruiting

MyelofibrosisPhase 2/Phase 3

Active, not recruiting

Acute Myeloid LeukemiaPhase 1/Phase 2

Active, not recruiting

Merkel Cell CarcinomaPhase 1/Phase 2

Active, not recruiting

Small Cell Lung CancerPhase 2

Active, not recruiting

Myeloid LeukemiaPhase 1/Phase 2

Active, not recruiting

Essential ThrombocythemiaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Nexavar

Bayer

Phase 3

12 2

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

12 3

Velcade

SShilpa Grover, MD, MPH

Phase 3

11 4

GM-CSF

YY-mAbs Therapeutics

Phase 3

1 5

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Phase 3

1 6

Daunorubicin or Idarubicin

Novartis

Phase 3

1 7

Azacitadine

AbbVie

Phase 3

1 8

KRT-232

KKartos Therapeutics, Inc.

Phase 2

2 9

Lodac

Astellas

Phase 3

1 10

Capoten

GSK

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia2 trials

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Terminated·KKartos Therapeutics, Inc.·Phase 1/2·NCT04113616·70 enrolled

TL-895 and KRT-232 Study in Acute Myeloid Leukemia

Unknown status·TTelios Pharma, Inc.·Phase 1/2·NCT04669067·18 enrolled

Myelofibrosis2 trials

Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

Unknown status·KKartos Therapeutics, Inc.·Phase 2·NCT04878003·52 enrolled

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

Unknown status·KKartos Therapeutics, Inc.·Phase 2/3·NCT03662126·385 enrolled

Small Cell Lung Cancer1 trial

KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

Terminated·KKartos Therapeutics, Inc.·Phase 2·NCT05027867·3 enrolled

Treatment1 trial

KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

Unknown status·KKartos Therapeutics, Inc.·Phase 1/2·NCT04640532·116 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Unknown status·KKartos Therapeutics, Inc.·Phase 1/2·NCT04502394·84 enrolled

4 more indications

Essential Thrombocythemia1 trial

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Unknown status·KKartos Therapeutics, Inc.·Phase 1/2·NCT04485260·36 enrolled

Myeloid Leukemia1 trial

KRT-232 and TKI Study in Chronic Myeloid Leukemia

Recruiting·KKartos Therapeutics, Inc.·Phase 1/2·NCT04835584·109 enrolled

Polycythemia Vera1 trial

KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

Unknown status·KKartos Therapeutics, Inc.·Phase 2·NCT03669965·20 enrolled

Merkel Cell Carcinoma1 trial

Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma

Unknown status·KKartos Therapeutics, Inc.·Phase 1/2·NCT03787602·115 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for KRT-232. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KRT-232 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KRT-232. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kartos Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKartos Therapeutics, Inc.

KRT-232

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Myeloid Leukemia2 trials

Myelofibrosis2 trials

Small Cell Lung Cancer1 trial

Treatment1 trial

Safety and Efficacy1 trial

Essential Thrombocythemia1 trial

Myeloid Leukemia1 trial

Polycythemia Vera1 trial

Merkel Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News